IBD's Persistent Unmet Need: Durable Remission and Mucosal Healing Remain the Missing Piece
核心洞察
Durable clinical remission remains a significant unmet need in IBD, with many patients still cycling through multiple therapies despite the number of available options.
Christian Thienel of Back Bay Life Science Advisors highlights mucosal healing and barrier function restoration as increasingly important, underaddressed therapeutic goals.
Emerging oral mechanisms—including SIK2 (搜索) inhibition, oral IL-23 (搜索) inhibitors such as icotrokinra, microRNA regulators, and TYK2 (搜索) inhibitors—are generating excitement in the IBD space.
Despite the growing number of therapies available for inflammatory bowel disease (搜索) (IBD), durable clinical remission remains one of the most persistent and significant unmet needs in the space, according to Christian Thienel, director at Back Bay Life Science Advisors. In a recent conversation with Pharmaceutical Executive, Thienel outlined the treatment and R&D barriers that continue to leave patients cycling through multiple therapies without achieving sustained relief.
"You might assume that with the number of therapies available, this is a relatively well-served market. But one of the most consistent findings from our research is that it isn't," Thienel said. "There are therapies that can induce clinical remission after initial treatment — but durability of remission remains a significant unmet need."
The Durability Gap
Thienel emphasized that a large number of patients are still cycling through multiple therapies, a signal in itself that new mechanisms of action and new delivery methods are needed. "Having additional options remains important precisely because durable efficacy continues to be a challenge," he noted.
The clinical consequences of this gap are stark. "If a patient with IBD has tried three or four different biologics or advanced therapies and hasn't achieved sustained remission, there are essentially no remaining options that physicians can confidently recommend at this point," Thienel explained. He added that there remains "considerable room to improve on efficacy — and specifically on rates of durable clinical remission."
Mucosal Healing as a Distinct Goal
Beyond durability, Thienel pointed to growing interest in mucosal healing as a distinct therapeutic goal. While single cytokine approaches are effective at reducing inflammation and producing an initial response, he described a growing perception among gastroenterology key opinion leaders (KOLs) that addressing mucosal healing more directly could unlock more durable responses.
"Addressing mucosal healing more directly, including restoring barrier function and addressing elements of the disease that aren't as directly targeted by individual cytokines, could be the key to achieving more durable responses and meaningfully improving patient quality of life," Thienel said. He acknowledged that this perspective is "somewhat speculative," but stressed that these components of the disease state are "increasingly seen as important, and they remain underaddressed by the current standard of care."
Emerging Oral Mechanisms
The oral treatment landscape reflects the significant unmet need identified in market research, with several emerging mechanisms generating excitement. Thienel highlighted SIK2 (搜索) inhibition — the mechanism Nimbus (搜索) is working on — as having distinctive advantages. "It not only reduces the activity of pro-inflammatory cytokines, but also has an effect on IL-10 and a mucosal healing mechanism that I think is a missing piece in a lot of the single cytokine-based approaches available today," he said.
Oral IL-23 (搜索) inhibitors are also drawing attention, particularly following the recent approval of icotrokinra. "The IL-23 mechanism is very well validated in the space, and the efficacy and safety data have been impressive," Thienel noted. However, he cautioned that, as seen with injectable IL-23 inhibitors, the single cytokine approach may not solve all the problems. "My hunch is that it probably won't — but icotrokinra is nonetheless expected to be a very successful product."
Additional mechanisms under discussion include microRNA regulators, which have shown "some interesting clinical signals," and TYK2 (搜索) inhibitors, which have "progressed considerably." Thienel noted that the TYK2 program Nimbus (搜索) developed with Takeda (搜索) is primarily advancing in psoriasis as a lead indication, though "there has been meaningful development activity around the TYK2 pathway in IBD as well."
"There is clearly a lot of activity in this space, which reflects what we saw from the market research: the unmet need on the oral side is significant," Thienel concluded. "The question is which of these mechanisms will best address what we believe are the fundamental remaining gaps — and each has its own set of advantages that will play out in the clinic."